Clinical trial NCT01078649: Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Official title: A Phase I, Open Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Properties of Orally Administered AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Solid Tumors
Lymphoma
Malignancy
Keywords: cancer
solid tumors
lymphoma
smac mimetic
IAP inhibitor
Phase I
Dose escalation
Lead sponsor: Debiopharm International SA
Sponsor class: INDUSTRY
First posted: 2010-03-02
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety profile and the maximum dose of Debio 1143 (AT-406) that can be given to humans. This study is also designed to measure how much Debio 1143 (AT-406) gets into the blood stream (pharmacokinetics), and how Debio 1143 (AT-406) interacts with proteins related to cancer that the drug is targeted to affect (pharmacodynamics).

Detailed description: Ascenta Therapeutics, Inc. is conducting a clinical trial of the compound Debio 1143 (AT-406), a small molecule second mitochondria-derived activator of caspase C (Smac) mimetic. In vivo and in vitro studies have demonstrated that Debio 1143 (AT-406) induces cell death in several tumor models by inhibiting XIAP (X linked IAP), cIAP-1 (cellular IAP-1) and cIAP-2 (cellular IAP-2), thus releasing initiator and effector caspases to promote apoptosis. This protocol is a Phase I, dose-escalation, open-label, multi-center study conducted in patients with advanced solid tumors and lymphomas to evaluate the safety, tolerability and pharmacology of Debio 1143 (AT-406) in humans when administered orally.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed solid tumor or lymphoma;
* Locally advanced or metastatic disease for which no life prolonging therapy is available and no standard therapy is judged appropriate by the investigator;
* Eastern Cooperative Oncology Group Performance Status ≤ 1;
* Adequate hematologic function as indicated by, ANC ≥ 1,500/mm3, Hgb \>9.0 g/dL, platelet count ≥ 100,000/mm3
* Adequate renal and liver function as indicated by serum creatinine ≤ 1.0 x ULN or creatinine clearance of \> 60 cc/min, serum albumin ≥ 3.0 gm/dL, total bilirubin \< 1.0 x ULN, AST and ALT ≤ 2.5 x ULN ; Alkaline phosphatase ≤2.5 x ULN
* Negative Hepatitis B and Hepatitis C testing;
* QTc interval ≤450ms.

Exclusion Criteria:

* Radiation within 14 days of study entry, thoracic radiation within 28 days of study entry. Patients who have received prior radiotherapy must have discontinued steroids for 14 days prior to study entry and be clinically stable;
* Not recovered to ≤ Grade 1 toxicity from prior radiotherapy or chemotherapy agents;
* Use or requirement for use of aspirin or aspirin containing products with \>81 mg of aspirin per day;
* History of gastrointestinal bleeding within 1 year;
* History of diabetes mellitus requiring treatment with oral agents or insulin;
* Active rheumatoid arthritis, active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation;
* Known or suspected Wilson's Disease, or other conditions that affect copper accumulation or regulation;
* Prior treatment with IAP inhibitors.

Primary outcomes:
measure: Maximally Tolerated Dose
timeFrame: 1 cycle, or any time during treatment
Secondary outcomes:
measure: Pharmacokinetic
timeFrame: Days 1-5 of Cycle 1
measure: Pharmacodynamic
timeFrame: Cycle 1
measure: Efficacy
timeFrame: After a minimum of 2 cycles.
measure: Correlation of Efficacy to Pharmacokinetic and/or Pharmacodynamic Effects of Debio 1143 (AT-406)
timeFrame: Anytime during Debio 1143 (AT-406) treatment
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Cancer Center
state: Michigan
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Debiopharm SA
name: Claudio Zanna, MD
role: STUDY_DIRECTOR
References:
citation: Hurwitz HI, Smith DC, Pitot HC, Brill JM, Chugh R, Rouits E, Rubin J, Strickler J, Vuagniaux G, Sorensen JM, Zanna C. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemother Pharmacol. 2015 Apr;75(4):851-9. doi: 10.1007/s00280-015-2709-8. Epub 2015 Feb 27.